Printer Friendly

BIOSITE DIAGNOSTICS AND IXSYS INC. ANNOUNCE RESEARCH AND DEVELOPMENT AGREEMENT

 BIOSITE DIAGNOSTICS AND IXSYS INC. ANNOUNCE
 RESEARCH AND DEVELOPMENT AGREEMENT
 SAN DIEGO, Aug. 6 /PRNewswire/ -- Ixsys Inc. and Biosite Diagnostics Inc., two San Diego-based biotech companies have announced that they have entered into a two-year research and development agreement. Ixsys, which is becoming recognized as a leader in the field of protein engineering, has developed proprietary technology that is applicable in the areas of monoclonal antibodies and peptides. The company intends to use this technology in developing therapeutic agents for treatment of various disease states including cancers, infectious diseases and immune disorders. Biosite's expertise is in the areas of development of biochemical techniques for antibody screening and immunoassay procedures. In addition to the research and development collaboration, the agreement provides for the exchange of certain proprietary technologies that have been developed by each of the parties. Ixsys will receive a non-exclusive license to practice certain Biosite technologies. Biosite will receive a non-exclusive license to practice certain Ixsys technologies in the area of in-vitro diagnostics. Specific terms of the research and development and licensing agreement are not disclosed.
 Ixsys is a privately held biotechnology firm that was founded in March 1990. Ixsys scientists have developed a system to generate human monoclonal antibodies in-vitro. One of the major obstacles that scientists have had to deal with in commercializing monoclonal antibodies as therapeutic agents is that human antibodies for most diseases have not been readily available. The alternative solution has been to use antibodies from other sources such as mice which may cause serious complications. In addition to this breakthrough technology, Ixsys scientists have also developed a bacterial system for the generation and identification of antibody and peptide libraries. These libraries, which may contain billions of antibody or peptide candidates, can be screened to identify candidates of potential interest. Once candidates of interest have been identified they can be manipulated to enhance its positive characteristics and eliminate undesirable characteristics. This technology, called codon based mutagenesis, is applicable to peptides as well as antibodies. The system mimics the antibody refining process that takes place in the human body but is much faster and more efficient.
 Biosite Diagnostics is a privately held biomedical company, based in San Diego, founded in 1988, that is focused on the development of a family of rapid, simple Immediate Response Diagnostic(TM) products based on the company's patented monoclonal antibody immunoassay technology. The company manufactures and markets Triage(TM), the first screening panel that will simultaneously and discretely detect the seven most commonly abused drugs in 10 minutes. The Triage device tests for PCP, benzodiazepines, cocaine, amphetamines, marijuana, opiates and barbiturates. A self-contained disposable device about the size of a credit card, Triage provides visible results in seven discrete drug detection zones located on the testing device. The device uses an all monoclonal antibody detection system that delivers sensitivity and specificity comparable to existing instrument-based systems. The test requires a simple three-step procedure to develop color in the drug detection zones, if there is drug present at or above the recommended cutoffs. Built-in procedural controls in every device validate the testing process and results. Triage appeals to a broad range of testing facilities and needs, such as hospital laboratories, emergency rooms, trauma units, neonatal departments and workplace testing and is currently being marketed in the United States.
 Biosite intends to apply the Ixsys codon based mutagenesis technology to improve antibody specificity by eliminating undesirable characteristics such as interferences and cross-reactivities that may cause false-positive reactions in tests currently employing traditional antibody sources. In addition, Biosite also intends to use the Ixsys technology to develop new testing products that, like the Triage Panel for Abused Drugs, are disposable tests which provide rapid, simple, highly accurate answers. The company intends to develop products for the detection and quantification of target molecules in the area of abused drugs, therapeutic drugs and fertility hormones.
 -0- 8/6/92
 /CONTACT: Michael Hanifin of Ixsys, 619-455-2356, or Kim Blickenstaff of Biosite, 619-455-4808/ CO: Ixsys Inc.; Biosite Diagnostics Inc. ST: California IN: MTC SU: LIC


JB-KJ -- SD005 -- 7690 08/06/92 15:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 6, 1992
Words:677
Previous Article:LASMO ACQUIRES 5.4 PERCENT STAKE IN PLAINS IN EXCHANGE FOR MIAMI FEE PROPERTIES
Next Article:HARCOR ENERGY CLOSES $3.0 MILLION PRIVATE EQUITY PLACEMENT
Topics:


Related Articles
STRATAGENE AND IXSYS ANNOUNCE SETTLEMENT OF TECHNOLOGY LITIGATION
IXSYS INC. GRANTED WORLDWIDE EXCLUSIVE LICENSE BY THE UNIVERSITY OF CALIFORNIA
IXSYS AND BRISTOL-MYERS SQUIBB ANNOUNCE RESEARCH AGREEMENT ON TUMOR-ASSOCIATED ANTIBODIES
IXSYS SCIENTISTS REPORT ABILITY TO ENHANCE THERAPEUTIC VALUE OF MONOCLONAL ANTIBODIES BEYOND THAT ACHIEVED BY THE HUMAN IMMUNE SYSTEM
Biosite(R) Diagnostics, Inc. is Nominated 5th Fastest-Growing Private Company by 'Inc. 500'
Biosite signs collaboration and phage display licensing agreement with MorphoSys.
Agenix and Biosite enter into license for D-dimer.
Biosite announces collaboration for cerebrovascular injury targets agreement signed with Banyan Biomarkers for potential development of novel targets.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters